News
STAB
0.0007
NaN%
--
Weekly Report: what happened at STAB last week (0513-0517)?
Weekly Report · 1d ago
Weekly Report: what happened at STAB last week (0506-0510)?
Weekly Report · 05/13 10:32
Weekly Report: what happened at STAB last week (0429-0503)?
Weekly Report · 05/06 10:37
Weekly Report: what happened at STAB last week (0422-0426)?
Weekly Report · 04/29 10:42
Weekly Report: what happened at STAB last week (0415-0419)?
Weekly Report · 04/22 10:35
Weekly Report: what happened at STAB last week (0408-0412)?
Weekly Report · 04/15 10:28
Weekly Report: what happened at STAB last week (0401-0405)?
Weekly Report · 04/08 10:32
Weekly Report: what happened at STAB last week (0325-0329)?
Weekly Report · 04/01 10:31
Weekly Report: what happened at STAB last week (0318-0322)?
Weekly Report · 03/25 10:33
Weekly Report: what happened at STAB last week (0311-0315)?
Weekly Report · 03/18 10:31
Weekly Report: what happened at STAB last week (0304-0308)?
Weekly Report · 03/11 10:29
Weekly Report: what happened at STAB last week (0226-0301)?
Weekly Report · 03/04 10:32
Weekly Report: what happened at STAB last week (0219-0223)?
Weekly Report · 02/26 10:40
Weekly Report: what happened at STAB last week (0212-0216)?
Weekly Report · 02/19 10:41
Weekly Report: what happened at STAB last week (0205-0209)?
Weekly Report · 02/12 10:34
Weekly Report: what happened at STAB last week (0129-0202)?
Weekly Report · 02/05 10:39
Weekly Report: what happened at STAB last week (0122-0126)?
Weekly Report · 01/29 10:32
Weekly Report: what happened at STAB last week (0115-0119)?
Weekly Report · 01/22 10:35
Weekly Report: what happened at STAB last week (0108-0112)?
Weekly Report · 01/15 10:33
Weekly Report: what happened at STAB last week (0101-0105)?
Weekly Report · 01/08 10:35
More
Webull provides a variety of real-time STAB stock news. You can receive the latest news about Statera Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About STAB
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The Company has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).